bristol melanoma drug extends survival in study
bristol-myers squibb co's eagerly anticipated experimental drug ipilimumab extended survival of previously untreated patients with advanced melanoma in a late stage study, the company said.
http://feeds.reuters.com/~r/reuters/healthnews/~3/x51prkuffp8/us-bristolmyers-melanoma-idustre72k7ct20110322
25200
22 Mar 2011 13:11:26
reuters
health